Omeros corporation announces publication of study results on the impact of omidria on opioid use and pain

Omeros corporation announced that results of a prospective, controlled study showing that its fda-approved ophthalmic drug omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published in the peer-reviewed journal clinical ophthalmology. the article, the effect of phenylephrine/ketorolac intracameral solution 1%/0.3% on pain and opioid use during cataract surgery, is authored by the study investigator eric d. donnenfeld, m.d., clinical professor of ophthalmology at new york university and recent past president of the american society of cataract and refractive surgery. omidria is approved by fda for prevention of miosis (pupil constriction) and for reduction in postoperative pain for adults and pediatric patients undergoing cataract or lens replacement surgery. the study objectives were to evaluate the effect of omidria compared to epinephrine on perioperative fentanyl use and pain in patients undergoing cataract surgery. sixty patients were prospectively assigned to have either omidria (41 patients) or epinephrine (19 patients) added to the irrigation solution used during surgery. patients in the omidria group were 6.7 times more likely not to require fentanyl, with 9.8% of omidria patients requiring fentanyl versus 42.1% of epinephrine patients (p = 0.006). in addition, mean visual analog scale (vas of 0-10) pain scores were significantly (48.9%) lower in the omidria group than in the epinephrine group (2.3 vs 4.5; p < 0.0001). the proportion of patients with vas scores = 3 (considered no to minimal pain) was significantly greater in the omidria group (85.0%) than in the epinephrine group (31.6%; p < 0.0001). omidria patients also were 94% less likely to require fentanyl or to have moderate-to-severe pain (vas = 4) than patients receiving epinephrine (odds ratio 0.06; 95% confidence interval 0.02-0.24). deaths in the u.s. from synthetic opioids, especially fentanyl, have increased more than 10-fold between 2013 and 2018 and are now involved in twice as many deaths as heroin. reduction of opioid use in cataract surgery patients is a public health focus and many studies have shown that the use of intraoperative opioids is associated with an increased postoperative opioid requirement. cataract surgery patients who receive an opioid prescription are 1.6 times more likely to be using opioids long-term than those who are not prescribed an opioid following cataract surgery.
OMER Ratings Summary
OMER Quant Ranking